Republic Republic Republic
  • Log in
Oops! We couldn’t find any results...
Can’t find a deal? Try advanced search.
Is something missing? Add your suggestion here.
Primary market Live deals Secondary market Buy and sell Republic Note Own a piece of Republic's upside Investor Network Membership Receive exclusive discounts and benefits
Republic Venture Opportunities for accredited investors
Republic Capital Multi-stage venture firm Republic Digital Crypto hedge fund
Wallet Manage your digital assets Mobile app Available on iOS or Android Learning center Explore investor resources FAQ Get your questions answered
Capital fundraising Raise on Republic Tokenized assets Design, launch, manage tokenized assets Sharedrops Gift equity as a reward
Advisory Access veteran web3 advisors Infrastructure Stake your digital assets Tokenization Deploy your assets on-chain Asset management Explore digital asset funds
Republic Capital In-house Venture Capital fund Broker dealer Regulated capital services
Log in Sign up

Republic Republic Republic
Oops! We couldn’t find any results...
Can’t find a deal? Try advanced search.
Is something missing? Add your suggestion here.
  • US
  • Log in
  • Sign up
All investors
Primary market Live deals Secondary market Buy and sell Republic Note Own a piece of Republic's upside Investor Network Membership Receive exclusive discounts and benefits
Accredited only
Republic Venture Opportunities for accredited investors
Institutional
Republic Capital Multi-stage venture firm Republic Digital Crypto hedge fund
More
Wallet Manage your digital assets Mobile app Available on iOS or Android Learning center Explore investor resources FAQ Get your questions answered
Spotlight deal
GVNR
GVNR
GVNR Protocol is the next evolution in cross-chain infrastructure for Web3, unlocking 3T$ of value.
Growth capital solutions
Capital fundraising Raise on Republic Tokenized assets Design, launch, manage tokenized assets
Sharedrops Gift equity as a reward
Web3 services
Advisory Access veteran web3 advisors Infrastructure Stake your digital assets Tokenization Deploy your assets on-chain Asset management Explore digital asset funds
Institutional services
Republic Capital In-house Venture Capital fund
Broker dealer Regulated capital services

Clear Health isn't accepting new investments

Clear Health’s deadline was November 12, 2023

Follow the company to stay updated on their progress, including future investment opportunities


Explore new investment opportunities:
View companies raising now
Campaign ended
Logo of Clear Health

Clear Health

Quickly growing digital clinic that treats complex skin conditions
B2C Wellness Healthtech
Facebook Telegram Twitter LinkedIn
Featured image of Clear Health
This is an SPV deal
Platinum Membership Eligible
Yes
Round
Seed
Valuation
$10M
Allocation
$550K
Deadline
November 12, 2023
Instrument
SAFE
Minimum investment
$2,500
Invest in Clear Health

Open for investment

Investors in Clear Health also invested in these companies. View more
Logo of Eli Roth's The Horror Section

Eli Roth's The...

A brand-new independent studio from an iconic horror...

Republic Funding Portal · Reg CF
Loading...
Pitch Updates Reviews 6
Invest Invest in Clear Health
Facebook Telegram Twitter LinkedIn
Closed on November 12, 2023. Information may not be up-to-date. Campaign closed on November 12, 2023. Information displayed may not be up-to-date.
Problem Solution Traction Biz. model Market Competition Funding Founders Disclaimer

Documents

Republic Deal Room Advisor (Republic Deal Room Advisor LLC, CRD# 31568) is hosting this Reg D 506(c) securities offering by Clear Health I, A Series of Republic Deal Room Master Fund, LP.
Company documents
Subscription Agreement Clear Health I - LPA.pdf Clear Health I - PPM.pdf
Loading

Hear from some of the 47 investors in Clear Health


Show more

Investment summary


Bootstrapped
High traction without any outside capital
Profitable
Company has been profitable for the past 6 months

Bootstrapped to profitability ($2.7M ARR), Clear Health is a quickly growing digital clinic that treats the physical + mental side of complex chronic skin disease affecting 85M+ Americans. The platform simplifies traditionally arduous treatment cycles for patients and physicians through seamless telemedicine evaluations, specialty prescription fulfillment, supporting skincare, and digitized admin management, while integrating dermatology and behavioral health through a novel collaborative care approach. Their initial beachhead market is chronic acne (Accutane) and then plan to move to Eczema (Dupixent), Psoriasis (Humira), and Rosacea (low dose accutane).  

This is a special purpose vehicle (SPV) formed to invest in Clear Health's Seed round:

  • 85M Americans = $47B+ Market Opportunity
  • Combines previously siloed systems into a single intuitive workflow
  • Bootstrapped to ~$3M ARR
  • 22% MoM ARR growth since launch
  • 65:1 LTV:CAC ratio
  • Have supported 6,500 patients to date

We have set up a webinar for you to meet the founder of Clear Health as well as ask any additional questions that you might have about the opportunity. 

You can hear from him directly Monday, August 14th at 1pm EST. 

Topic: Clear Health <> Republic Deal Room Webinar 

Registration Link

In less than 12 months of operation, the founders have bootstrapped the company to a profitable $2.7M ARR (22% MoM Growth) → $4.5M EO23 → $15M EO24, with an 65:1 LTV:CAC ratio. To date, they have supported 6,500 patients  and plan to use these funds to bring their dermatologists in house and invest more heavily in paid marketing (currently only spending $5k / mo on paid acquisition) which they expect will yield stronger margins + significant revenue growth. Today 75% of their patients are covered by insurance and 25% are uninsured customers representing 50% of revenue.

Deal Highlights:

85M Americans / $47B+ Market Opportunity:  85M+ Americans in the US suffer from chronic skin conditions including acne, eczema, psoriasis, and more. The total addressable market for chronic skin diseases is $47B+ and is expected to grow at a 7.4% CAGR through 2027, driven by societal and environmental factors such as the increasing prevalence of chronic skin diseases, rising demand for effective treatments, and the growing awareness of skin health. Clear Health is starting with the $1.2B Accutane market that is used by over 500k Americans every year.

A Convoluted Care System: The current in-person care model for chronic skin disease is inaccessible, impersonal, complex to manage, and doesn’t take behavioral health into account. For patients, this leads to delays in treatment, poor adherence, and expensive processes - ultimately leading to sub-par results. The emotional impact that the current in-person care model has on acne patients has contributed to 70%+ patients suffering from depression, even though mental illness is typically not addressed as part of the care. For healthcare personnel (HCPs), the current in-person care model leads to bloated admin costs, burnout, and poor quality of care - the focus becomes paperwork and coordination instead of patients, leading to up to 6x more communication, longer registration time, and higher admin costs. This is where Clear Health comes in.

Innovative Solution: Clear Health combines previously siloed systems into a single intuitive workflow to reduce hours of admin work down to minutes. Clear Health is bridging the skin health journey from the dermatologist office to the pharmacy + retail beauty store through a digital-first approach, driving convenience, affordability, and superior results for customers. The patient interfaces with a seamless treatment portal that manages all the complexity from labs to required contraception, to post-treatment therapy. With Clear Health, patients can access everything from doctor-led telemedicine, specialty pharmacy prescriptions, bundled supporting items and skincare items, mental health services, and more from the comfort of their homes. For HCPs, all work functions can be accessed through one easy system, including telemedicine, custom electronic medical records specifically designed for skin disease treatment, insurance coverage pre-authorizations, HIPAA Efax, and digital reminders. Their initial beachhead market is chronic acne (Accutane) and then plan to move to Eczema (Dupixent), Psoriasis (Humira), and Rosacea (low dose accutane).  

Bootstrapping to ~$3M ARR: In less than 12 months of operation, the founders have bootstrapped the company to a profitable $2.7M ARR (22% MoM Growth) → $5M EO23 → $15M EO24 → $30M EO25, with a standout 65:1 LTV:CAC ratio. To date, they have supported 6,500 patients (3k monthly right now) and plan to use these funds to bring their dermatologists in house and invest more heavily in paid marketing (currently only spending $5k / mo on paid acquisition) which they expect will yield stronger margins + significant revenue growth. Today 75% of their patients are covered by insurance and 25% are uninsured customers representing 50% of revenue.

Founding Team: The founding team has an impressive background across investing and healthcare services, as well as an understanding of the impact that chronic skin conditions can have on patients. The company is led by Michael Chang (CEO), who previously worked in consumer private equity at Roark Capital Group, and has experienced chronic acne first-hand and the impact that Accutane can have on the condition. Michael is joined by Wen-Chen Chiu (COO), who spent 10+ years at Bridgewater Associates, the largest hedge fund in the world, and is also a licensed esthetician. Dr. Aaron Farberg, MD/FAAD (Medical Director), is a Mount Sinai-trained Mohs surgeon and dermatologist with extensive collaborative care experience in major hospital settings. The founding team is joined by an advisory board, Danielle V Samuels, PhD, whose expertise follows the connection between mental health and acne, and Johann Verheem, former Head of Product at Pro-Activ. 

Reasonable $16M Valuation: In the context of a quickly growing $2.7 ARR → $5M EO23, we are investing on what we deem a reasonable $16.7M valuation, which equates to 3.3x revs EO23. The founders plan to raise a $10M+ Series A in 2024, so this is an opportunity to get in before then.

Problem


The current in-person care model for chronic skin disease is inaccessible, complex to manage, and doesn’t take behavioral health into account. For patients, this leads to delays in treatment, poor adherence, and expensive processes - ultimately leading to sub-par results. The emotional impact that the current in-person care model has on acne patients has contributed to 70%+ patients suffering from depression, even though mental illness is typically not addressed as part of the care. For healthcare personnel (HCPs), the current in-person care model leads to bloated admin costs, burnout, and poor quality of care - the focus becomes paperwork and coordination instead of patients, leading to up to 6x more communication, longer registration time, and higher admin costs.


Solution


Clear Health is a quickly growing digital clinic that treats the physical + mental side of complex chronic skin disease affecting 85M+ Americans.

Clear Health is bridging the skin health journey from the dermatologist office to the pharmacy + retail beauty store through a digital-first approach, driving convenience, affordability, and superior results for customers. The patient interfaces with a seamless treatment portal that manages all the complexity from labs to contraception, to post-treatment therapy. With Clear Health, patients can access everything from doctor-led telemedicine, specialty pharmacy prescriptions, bundled supporting items and skincare items, mental health services, and more from the comfort of their homes. For HCPs, all work functions can be accessed through one easy system, including telemedicine, custom electronic medical records specifically designed for skin disease treatment, insurance coverage pre-authorizations, HIPAA Efax, and digital reminders. Clear Health combines previously siloed systems into a single intuitive workflow to reduce hours of admin work down to minutes.

Traction


  • In less than 12 months of operation, the founders have bootstrapped the company to a profitable $2.7M ARR (22% MoM Growth) → $4.5M EO23 → $15M EO24, with an incredible 65:1 LTV:CAC ratio. 

  • 3k monthly patients today → 4-5k EO23 → 10k EO24

  • The company has grown consistently since launch with average 22% MoM growth  

  • Average 65x+ LTV/CAC

  • ~$8 CAC / $110 AOV / $1K - $5K total treatment

  • 40% blended gross margins → 75% at maturity

  • 25% of customers are uninsured (representing 50% of revs)

  • Cuts the typical resolution process down for Accutane related skin conditions by 70%+

  • The company is solely focusing on the $1.2B Accutane market, before moving into other acne solutions, as well as Rosacea, Eczema, and Psoriasis solutions.

Business model


Clear Health charges a simple telemedicine evaluation fee of $59 for an initial visit or follow-up. On an initial visit, the company pays their physicians $40, for a gross margin of 32%. Follow-up visits pay the physician $20, for a gross margin of 66%. 

Market


85M+ Americans in the US suffer from chronic skin conditions including acne, eczema, psoriasis, and more. This is a problem space that I relate to personally as I suffer from psoriasis personally. The total addressable market for chronic skin diseases is $47B+ and is expected to grow at a 7.4% CAGR through 2027, driven by societal and environmental factors such as the increasing prevalence of chronic skin diseases, rising demand for effective treatments, and the growing awareness of skin health. Clear Health is starting with the $1.2B Accutane market that is used by over 500k Americans every year.

Competition


  • Hims & Hers provides prescription and over-the-counter products for men and women, including skin care products.

  • Curology provides personalized skin care prescriptions to patients.

  • DermatologistOnCall connects patients with board-certified dermatologists for video appointments and treatment of skin conditions.

  • Mandel specializes in dermatology, offering video appointments, prescription refills, and skin consultations.

  • Roman provides men with convenient and affordable access to healthcare services, including erectile dysfunction, hair loss, and skin care.

Funding


The company plans on using the funds from this round to supercharge growth via new product lines and key hires before expanding into adjacent skin diseases, Rosacea, Eczema, and Psoriasis.

This is a $1M Seed on a $16.7M post-money SAFE. 

Funds from this round will be used to scale and accomplish the following milestones ahead of their much larger Series A:

  • Key hires

  • In-house physicians 

  • Full-scale collaborative care implementation

  • Micro-dose Accutane ($5B SOM)

  • Cetaphil/Aquapho competitive skincare line

  • Achieve $20M+ ARR in 18 months 

Founders


The founding team has an impressive track record of investing and medical services, along with personal experiences with skin diseases and solutions. 

Michael Chang (CEO) - Previously worked in consumer private equity at Roark Capital Group, and has experienced chronic acne first-hand and the impact that Accutane can have on the condition. 

Wen-Chen Chiu (COO) Spent 10+ years at Bridgewater Associates, the largest hedge fund in the world, and is also a licensed esthetician. 

Dr. Aaron Farberg, MD/FAAD (Medical Director), is a Mount Sinai-trained Mohs surgeon and dermatologist with extensive collaborative care experience in major hospital settings. 

The founding team is joined by an advisory board, Danielle V Samuels, PhD, whose expertise follows the connection between mental health and acne, and Johann Verheem, former Head of Product at Pro-Activ.

Disclaimer


In addition to the carried interest Republic Deal Room Advisor LLC is entitled to for the syndicated investments it organizes, certain principals of Republic Deal Room Advisor LLC may have a personal interests in these investments, as disclosed below. When making an investment decision please review any applicable disclosures as they represent pre-existing financial interests held by those principals of Republic Deal Room Advisor LLC.

We do not represent that the information contained herein is accurate or complete, and it should not be relied upon as such. Opinions expressed herein are subject to change without notice. Certain information contained herein (including any forward-looking statements and economic and market information) has been obtained from and/or prepared by the Company or other third-party sources and in certain cases has not been updated through the date hereof. While such sources are believed to be reliable, Republic Deal Room Advisor LLC does not assume any responsibility for the accuracy or completeness of such information. Republic Deal Room Advisor LLC does not undertake any obligation to update the information contained herein as of any future date.

Documents

Republic Deal Room Advisor (Republic Deal Room Advisor LLC, CRD# 31568) is hosting this Reg D 506(c) securities offering by Clear Health I, A Series of Republic Deal Room Master Fund, LP.
Company documents
Subscription Agreement Clear Health I - LPA.pdf Clear Health I - PPM.pdf
Logo of Clear Health

Clear Health

Clear Health successfully raised $309,300 from 47 investors on November 12, 2023
Republic

Giving everyone access to early-stage startup investing

For investors
  • Why invest
  • How it works
  • FAQ
  • Risks
  • Privacy policy
  • Accessibility
  • Cookie Preferences
  • Form CRS
For startups
  • Why raise
  • Learn
  • FAQ
  • Instruments
  • Crowd SAFE
  • Tokenized assets
Company
  • About
  • Journal
  • Events
  • Contact
  • We're hiring!
Dollar Refer a startup, get $2,500
Dollar Refer a startup, get $2,500

Invest in the app

Android app iOS app

Invest in the app

Android app iOS app

This site (the "Site") is owned by OpenDeal Inc. and hosted by its wholly owned subsidiary Republic Core LLC, a technology services provider which is not a registered broker-dealer, investment adviser, or securities intermediary. Neither Republic Core LLC nor OpenDeal Inc. provide investment advice, endorsement, analysis, or recommendations with respect to any securities. All securities listed here are being offered by, and all information included on this Site is the responsibility of, the applicable issuer of such securities. The intermediary facilitating the offering will be identified in such offering’s documentation. Certain pages discussing the mechanics and providing educational materials may refer to OpenDeal Inc. and its affiliates collectively as “Republic”, solely for explanatory purposes.

This page and all other pages that are branches are maintained by Republic Deal Room Advisor LLC, an exempt reporting investment adviser, which is a subsidiary of OpenDeal Inc. Republic Deal Room Advisor LLC may cancel an offering for any reason, and there is no guarantee that a specific allocation will be made available. Successful offerings are syndicated through a special purpose funds, and Republic Deal Room Advisor LLC or an affiliate will charge a carried interest and management fee as an investment advisor to the relevant fund. Early stage investing is highly risky and subject to total loss of capital, and is suitable for experienced investors only. Investors co-investing in Republic Deal Room Advisor LLC's syndicates are responsible for making their own investment decisions. Republic Deal Room Advisor LLC provides investment advisory services to its investment funds only.

By accessing links to other pages on the Site and thereby accessing the Site and any pages thereof, you agree to be bound by the Republic Deal Room Advisor LLC's Terms of Use and Privacy Policy, please also see Republic Deal Room Advisor LLC's Form ADV.

Investors should verify any issuer information they consider important before making an investment.

Invest in startups using your credit card
You can invest using your credit card

Made in SF/NYC